[18F]FAPI-74 PET/CT在特发性肺纤维化中的初步结果
本研究前瞻性纳入8例特发性肺纤维化(IPF)患者,均行[18F]FAPI-74 PET/CT与HRCT,并与无肺纤维化疾病的对照组比较。结果显示纤维化活动体积与Hounsfield标度、肺活量及弥散功能呈正相关,初步证实[18F]FAPI-74可为IPF肺纤维化改变提供可行的无创评估方法。
要点
- 8例IPF患者行[18F]FAPI-74 PET/CT与HRCT并与无肺纤维化对照组比较。
- 纤维化活动体积与Hounsfield标度、肺活量及弥散功能呈正相关。
- 初步结果支持[18F]FAPI-74可作为IPF肺纤维化改变的无创评估方法。
核心结论
- 初步结果证实研究假设,即[18F]FAPI-74可为IPF患者的肺纤维化改变提供可行的无创评估方法。
研究设计与样本
- 前瞻性研究,纳入8例特发性肺纤维化(IPF)患者,均行[18F]FAPI-74 PET/CT与HRCT扫描。
- 设无任何纤维化肺疾病的对照组,并将纤维化肺区的示踪剂摄取与影像学及临床参数联合分析。
主要发现
- 观察到纤维化活动体积与Hounsfield标度、肺活量及弥散功能之间呈正相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrosing interstitial lung disease with a poor prognosis. 68Ga-labeled FAP ligands exhibited highly promising results due to the crucial role of activated fibroblasts in fibrosis imaging of the lung. However, 18F-labeled FAP ligands might provide qualitatively much higher imaging results with accompanying economic benefits due to large-scale production. Thus, we sought to investigate the potential of [18F]FAPI-74 prospectively in a small patient cohort. METHODS: Eight patients underwent both [18F]FAPI-74-PET/CT and HRCT scans and were then compared with a control group without any fibrosing pulmonary disease. The tracer uptake of fibrotic lung areas was analyzed in synopsis with radiological and clinical parameters. RESULTS: We observed a positive correlation between the fibrotic active volume, the Hounsfield scale, as well as the vital and diffusing capacity of the lung. CONCLUSION: The initial results confirm our assumption that [18F]FAPI-74 offers a viable non-invasive assessment method for pulmonary fibrotic changes in patients with IPF.
引用
- Mori Y, Kramer V, Novruzov E, et al. Initial results with [18F]FAPI-74 PET/CT in idiopathic pulmonary fibrosis. Eur J Nucl Med Mol Imaging. 2023. PMID: 38117298. doi:10.1007/s00259-023-06564-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。